| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 368 | 2020 |
| High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial A Zapatero, A Guerrero, X Maldonado, A Alvarez, CG San Segundo, ... The Lancet Oncology 16 (3), 320-327, 2015 | 335 | 2015 |
| Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: Dose–volume effect A Zapatero, F García-Vicente, I Modolell, P Alcántara, A Floriano, ... International Journal of Radiation Oncology* Biology* Physics 59 (5), 1343-1351, 2004 | 92 | 2004 |
| Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis AU Kishan, Y Sun, H Hartman, TM Pisansky, M Bolla, A Neven, A Steigler, ... The lancet oncology 23 (2), 304-316, 2022 | 89 | 2022 |
| Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with … A Zapatero, F Valcárcel, FA Calvo, R Algás, A Béjar, J Maldonado, S Villá Journal of clinical oncology 23 (27), 6561-6568, 2005 | 84 | 2005 |
| Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021 S Gillessen, A Armstrong, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, ... European urology 82 (1), 115-141, 2022 | 76 | 2022 |
| Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy A Zapatero, CM De Vidales, R Arellano, Y Ibañez, G Bocardo, M Perez, ... Urology 80 (5), 1056-1062, 2012 | 71 | 2012 |
| PEACE V–Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial A De Bruycker, A Spiessens, P Dirix, N Koutsouvelis, I Semac, ... BMC cancer 20, 1-12, 2020 | 69 | 2020 |
| The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy J Morote, A Gómez-Caamaño, JL Alvarez-Ossorio, D Pesqueira, ... The Journal of urology 193 (6), 1963-1969, 2015 | 69 | 2015 |
| Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European urology 83 (3), 267-293, 2023 | 65 | 2023 |
| Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO … SGC Kroeze, M Pavic, K Stellamans, Y Lievens, C Becherini, M Scorsetti, ... The lancet oncology 24 (3), e121-e132, 2023 | 64 | 2023 |
| Updated results of bladder-sparing trimodality approach for invasive bladder cancer A Zapatero, CM de Vidales, R Arellano, G Bocardo, M Pérez, P Ríos Urologic Oncology: Seminars and Original Investigations 28 (4), 368-374, 2010 | 63 | 2010 |
| Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC … S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ... European journal of cancer 185, 178-215, 2023 | 58 | 2023 |
| Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus T Zilli, V Achard, A Dal Pra, N Schmidt-Hegemann, BA Jereczek-Fossa, ... Radiotherapy and Oncology 176, 199-207, 2022 | 47 | 2022 |
| Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? A Zapatero, R Mínguez, S Nieto, CM de Vidales, F García-Vicente European urology 55 (4), 902-910, 2009 | 45 | 2009 |
| Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy A Zapatero, M Morente, S Nieto, CM de Vidales, C Lopez, M Adrados, ... Urologic Oncology: Seminars and original investigations 32 (8), 1327-1332, 2014 | 36 | 2014 |
| Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: Results from the DART 01/05 randomized phase 3 … A Zapatero, A Guerrero, X Maldonado, A Álvarez, ... International Journal of Radiation Oncology* Biology* Physics 96 (2), 341-348, 2016 | 34 | 2016 |
| High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial A Zapatero, A Guerrero, X Maldonado, A Álvarez, CG San-Segundo, ... The Lancet Oncology 23 (5), 671-681, 2022 | 28 | 2022 |
| Sensitivity of a helical diode array device to delivery errors in IMRT treatment and establishment of tolerance level for pretreatment QA F García‐Vicente, V Fernández, R Bermüdez, A Gómez, L Pérez, ... Journal of Applied Clinical Medical Physics 13 (1), 111-123, 2012 | 27 | 2012 |
| Invasive bladder cancer: A single‐institution experience with bladder‐sparing approach A Zapatero, C Martin de Vidales, A Marin, L Cerezo, R Arellano, ... International journal of cancer 90 (5), 287-294, 2000 | 27 | 2000 |
